Category: Blog Post

Leveraging Translational Tools for Product Development
August 11, 2021 Blog Post Snowfish

In the life science industry, product development has evolved into a costly endeavor. Translational tools seek to change this. Despite the promise of a novel molecule, it is an unfortunate fact of the life science industry that an overwhelming majority of discoveries will never result in new treatments. In fact, Valdes et al. 2018 finds

mRNA Vaccines: What to Know to Get Ahead of the Latest Industry Trend
July 13, 2021 Blog Post Snowfish

Despite being discovered 65 years ago, messenger-RNA (mRNA), specifically mRNA vaccines, is making waves in the pharmaceutical industry. Pfizer/Biotech and Modernas’ COVID-19 vaccines credit their success to mRNA, causing other industry players to follow suit. Sanofi just announced it will invest $476 million dollars into the development of mRNA based vaccines. As with any new

7 Factors Life Science Professionals Miss When Analyzing the Market Landscape
June 3, 2021 Blog Post Snowfish

With billions of dollars on the line, a thorough analysis of the market landscape for your life science product is of utmost importance. Entering new markets is a high stakes hurdle for life science companies. Wouters et al. estimates that it costs an average of $1.3 billion to bring a new medicine to market.  Compounding

Why the Pfizer COVID Pill Will Break the Pandemic
May 13, 2021 Blog Post Snowfish

The Pfizer COVID pill is the latest feat of strength from the New York-based pharmaceutical firm. To pair with its robust vaccine, Pfizer recently announced the development of an experimental antiviral drug that, for all intents and purposes, will break the pandemic. Unfortunately, in a pandemic, a vaccine on its own has never been enough.

What is Stakeholder Analysis in Life Science? Why should you do it?
April 13, 2021 Blog Post Snowfish

“Stakeholder Analysis and Engagement are critical to the launch and staying power of your product.” You have heard that wisdom before, but on top of seven to nine phone calls a day and hours spent in meetings, you may not have time to complete a truly thorough Stakeholder Analysis. Still, you are bombarded with calls

Three Product Development Secrets: Learnings from Pfizer, Moderna, and J&J
April 6, 2021 Blog Post Snowfish

In possibly the greatest product development race of this century, Pfizer, Moderna, and Johnson and Johnson (J&J) have emerged victorious. These firms beat out 6 other pharmaceutical companies, including titans AstraZeneca PLC and GlaxoSmithKline, in the race to develop a COVID-19 vaccine. A lot of lessons should be learned from this pandemic. For this post,

Antibody Ambivalence: Why the Constraints on Monoclonal Antibodies in COVID-19
February 10, 2021 Blog Post Snowfish

Despite an average vaccination rate of 1.41 million doses per day in the U.S, the pandemic continues to take its toll on the population. In our last post, my colleague wrote of his relative who unfortunately contracted coronavirus. However, we are pleased to inform that she received a monoclonal antibodies treatment, and is currently recovering.

COVID-19 Monoclonal Antibodies: Missing the Critical Window is Killing People
January 22, 2021 Blog Post Snowfish

This past week, a dear family member, an older adult, found that she has COVID-19. After her husband was diagnosed and hospitalized, she got tested and was shocked to find herself positive. She immediately called her primary care physician he did not send her immediately for any treatment such as a monoclonal antibody. In fact,

COVID-19 Vaccine: Engagement of Stakeholders
January 14, 2021 Blog Post Snowfish

The year is 2021 and it is late spring. With COVID-19 vaccine quantities bountiful, you return to your preferred clinic after a year-long absence to receive the first of your two injections. In the small sterile office, it feels like you and your health care provider are the only ones in the room, a simple

Amarin Decision Update: To Europe and Beyond
December 10, 2020 Blog Post Snowfish

As the world waits for COVID-19 vaccines to become widely available, Amarin experiences a different form of anticipation, one which will see the fate of its own profitability. Our previous blog post on Amarin highlighted the disastrous effects of a U.S Court of Appeals decision to invalidate Amarin’s six patents. To briefly recap, while the